ORIGINAL ARTICLE   

Minerva Cardiology and Angiology 2024 Nov 29

DOI: 10.23736/S2724-5683.24.06639-0

Copyright © 2024 EDIZIONI MINERVA MEDICA

language: English

Inflammation-related markers in COVID-19 infection and ST-segment elevation myocardial infarction

Nart Z. BAYTUĞAN ¹ ✉, Hasan C. KANDEMIR ², Aziz İ. ÇELIK ¹, Tahir BEZGIN ¹

¹ Gebze State Hospital, Gebze, Kocaeli, Türkiye; ² Kocaeli State Hospital, Kocaeli, Türkiye

BACKGROUND: The aim of this study is to investigate the association between inflammation-related markers in COVID-19 infection and ST-segment elevation myocardial infarction (STEMI).
METHODS: We conducted an observational, single-center, retrospective study between January 2020 and November 2022. A total of 149 patients aged between 34 and 90 years, 28.2% (N.=42) female and 71.8% (N.=107) male, were included in the study. Systemic immune-inflammation index (SII), systemic inflammation-response indexes (SIRI), platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) were calculated for each patient. The patients were divided into two groups based on their presence or absence of a confirmed SARS-CoV-2 infection.
RESULTS: During the in-hospital follow-up, mortality occurred in 12% (N.=20) of patients. Among the COVID-19 (+) and STEMI group, the mortality rate was 24.3% (N.=10), while it was 5.6% (N.=6) in the COVID-19 (-) and STEMI group (P=0.001). In multivariate logistic regression analysis, SII ([HR] = 7.198 [1.423-36.411], P=0.017) and PLR ([HR] = 5.762 [1.783-18.619], P=0.003) remained significant risk factor for mortality.
CONCLUSIONS: The SII, SIRI, NLR, and PLR are relatively new, simple, and effective inflammation-related markers that determine mortality risk in STEMI patients.

KEY WORDS: ST-segment elevation myocardial infarction; COVID-19; Inflammation